Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 304

1.

Strategies for eliminating PrP(c) as substrate for prion conversion and for enhancing PrP(Sc) degradation.

Gilch S, Nunziante M, Ertmer A, Schätzl HM.

Vet Microbiol. 2007 Aug 31;123(4):377-86. Review.

PMID:
17493775
2.

Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication.

Nunziante M, Kehler C, Maas E, Kassack MU, Groschup M, Schätzl HM.

J Cell Sci. 2005 Nov 1;118(Pt 21):4959-73.

3.

Aptamers against prion proteins and prions.

Gilch S, Schätzl HM.

Cell Mol Life Sci. 2009 Aug;66(15):2445-55. doi: 10.1007/s00018-009-0031-5. Review.

PMID:
19396399
4.

Peptide aptamers expressed in the secretory pathway interfere with cellular PrPSc formation.

Gilch S, Kehler C, Schätzl HM.

J Mol Biol. 2007 Aug 10;371(2):362-73.

PMID:
17574575
5.
6.

The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells.

Ertmer A, Gilch S, Yun SW, Flechsig E, Klebl B, Stein-Gerlach M, Klein MA, Schätzl HM.

J Biol Chem. 2004 Oct 1;279(40):41918-27.

PMID:
15247213
7.

Trapping prion protein in the endoplasmic reticulum impairs PrPC maturation and prevents PrPSc accumulation.

Cardinale A, Filesi I, Vetrugno V, Pocchiari M, Sy MS, Biocca S.

J Biol Chem. 2005 Jan 7;280(1):685-94.

PMID:
15513919
8.

Towards cellular receptors for prions.

Lee KS, Linden R, Prado MA, Brentani RR, Martins VR.

Rev Med Virol. 2003 Nov-Dec;13(6):399-408. Review.

PMID:
14625887
9.

Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.

Kim Y, Han B, Titlow W, Mays CE, Kwon M, Ryou C.

Antiviral Res. 2009 Nov;84(2):185-93. doi: 10.1016/j.antiviral.2009.09.002.

PMID:
19748523
10.

Prion diseases: from molecular biology to intervention strategies.

Nunziante M, Gilch S, Schätzl HM.

Chembiochem. 2003 Dec 5;4(12):1268-84. Review.

PMID:
14661267
12.

Neuroendocrine cultured cells counteract persistent prion infection by down-regulation of PrPc.

Aguib Y, Gilch S, Krammer C, Ertmer A, Groschup MH, Schätzl HM.

Mol Cell Neurosci. 2008 May;38(1):98-109. doi: 10.1016/j.mcn.2008.02.004.

PMID:
18387818
13.

Discriminating between cellular and misfolded prion protein by using affinity to 9-aminoacridine compounds.

Phuan PW, Zorn JA, Safar J, Giles K, Prusiner SB, Cohen FE, May BC.

J Gen Virol. 2007 Apr;88(Pt 4):1392-401.

PMID:
17374787
15.

Prion protein self-interactions: a gateway to novel therapeutic strategies?

Rigter A, Langeveld JP, van Zijderveld FG, Bossers A.

Vaccine. 2010 Nov 16;28(49):7810-23. doi: 10.1016/j.vaccine.2010.09.012. Review.

PMID:
20932496
16.

Prion protein functions and dysfunction in prion diseases.

Sakudo A, Ikuta K.

Curr Med Chem. 2009;16(3):380-9. Review.

PMID:
19149584
17.

Lithium induces clearance of protease resistant prion protein in prion-infected cells by induction of autophagy.

Heiseke A, Aguib Y, Riemer C, Baier M, Schätzl HM.

J Neurochem. 2009 Apr;109(1):25-34. doi: 10.1111/j.1471-4159.2009.05906.x.

18.

Antibodies to a nonconjugated prion protein peptide 95-123 interfere with PrP( Sc ) propagation in prion-infected cells.

Oboznaya MB, Gilch S, Titova MA, Koroev DO, Volkova TD, Volpina OM, Schätzl HM.

Cell Mol Neurobiol. 2007 May;27(3):271-84.

PMID:
17205391
19.

Prion-protein-specific aptamer reduces PrPSc formation.

Proske D, Gilch S, Wopfner F, Schätzl HM, Winnacker EL, Famulok M.

Chembiochem. 2002 Aug 2;3(8):717-25.

PMID:
12203970
20.

Gene and cell therapy for prion diseases.

Relaño-Ginés A, Gabelle A, Lehmann S, Milhavet O, Crozet C.

Infect Disord Drug Targets. 2009 Feb;9(1):58-68. Review.

PMID:
19200016
Items per page

Supplemental Content

Support Center